{"title":"Statistics of Visceral Sarcoma in Japan: Report From the Population‐Based National Cancer Registry (NCR) in Japan","authors":"Shudai Muramatsu, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Yu Toda, Shintaro Iwata, Eisuke Kobayashi, Takahiro Higashi, Masahiko Ikeuchi, Akira Kawai","doi":"10.1002/jso.27867","DOIUrl":null,"url":null,"abstract":"Background and ObjectivesSarcomas developing in the visceral organs are extremely rare, with no previous reports to describe their national epidemiology. We analyzed Japanese domestic statistics for visceral sarcoma, using the National Cancer Registry (NCR) in Japan, a population‐based database launched in 2016.MethodsWe identified 3245 cases of visceral sarcomas in the NCR dated 2016–2019 to analyze demographic and disease information, initial diagnostic process, volume and type of the hospitals, treatment, and prognosis.ResultsVisceral sarcoma shows a higher prevalence in the older generation (60+ years), with a significant male predominance (<jats:italic>p</jats:italic> = 0.006). Leiomyosarcomas occurred frequently in the gastrointestinal tract (<jats:italic>N</jats:italic> = 240; 39.5%), and angiosarcomas in the liver, gall bladder, pancreas, and spleen (<jats:italic>N</jats:italic> = 244; 43.9%). Visceral sarcomas were often treated in facilities of lower volume without specific adjuvant treatments (<jats:italic>p</jats:italic> < 0.001). The cumulative 3‐year overall survival was 44.8%, and several factors such as surgery or absence of chemotherapy positively affected survival.ConclusionsThis is the first nationwide study in Japan to analyze the inclusive epidemiology of visceral sarcomas. Visceral sarcomas are characterized by senior and male predominance with relatively poor prognosis, often managed in nonspecialized facilities and rarely with adjuvant therapies. Several histologic subtypes had the propensity to develop in specific organs.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.27867","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and ObjectivesSarcomas developing in the visceral organs are extremely rare, with no previous reports to describe their national epidemiology. We analyzed Japanese domestic statistics for visceral sarcoma, using the National Cancer Registry (NCR) in Japan, a population‐based database launched in 2016.MethodsWe identified 3245 cases of visceral sarcomas in the NCR dated 2016–2019 to analyze demographic and disease information, initial diagnostic process, volume and type of the hospitals, treatment, and prognosis.ResultsVisceral sarcoma shows a higher prevalence in the older generation (60+ years), with a significant male predominance (p = 0.006). Leiomyosarcomas occurred frequently in the gastrointestinal tract (N = 240; 39.5%), and angiosarcomas in the liver, gall bladder, pancreas, and spleen (N = 244; 43.9%). Visceral sarcomas were often treated in facilities of lower volume without specific adjuvant treatments (p < 0.001). The cumulative 3‐year overall survival was 44.8%, and several factors such as surgery or absence of chemotherapy positively affected survival.ConclusionsThis is the first nationwide study in Japan to analyze the inclusive epidemiology of visceral sarcomas. Visceral sarcomas are characterized by senior and male predominance with relatively poor prognosis, often managed in nonspecialized facilities and rarely with adjuvant therapies. Several histologic subtypes had the propensity to develop in specific organs.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.